Edesa Biotech, Inc. (EDSA) stock
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
$1.89−0.05 (-2.58%)
Close on Nov 16, 2026Market cap $18.22MP/E –Yield –
Edesa Biotech gross margin
Gross margin is gross profit as a percentage of revenue.
Edesa Biotech's gross margin for the twelve months ending Jun 30, 2021 was -362.8%. For fiscal 2020 it was 94.6%, against 37.1% the year before. The highest annual figure on record is 94.6% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | 94.6% | +57.6 |
| FY2018 | Sep 30, 2018 | 37.1% | +46.6 |
| FY2017 | Sep 30, 2017 | -9.5% | −45.2 |
| FY2016 | Sep 30, 2016 | 35.6% | +61.7 |
| FY2014 | Aug 31, 2014 | -26.1% | −115.6 |
| FY2013 | Aug 31, 2013 | 89.5% | +138.5 |
| FY2012 | Aug 31, 2012 | -49.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -362.8% | −462.8 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | 98.7% | +34.2 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | 90.9% | +93.4 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | 96.5% | +10.2 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | 100.0% | +780.5 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | 64.5% | +342.2 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -2.5% | +10.9 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | 86.3% | +41.7 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -680.5% | −737.9 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -277.7% | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -13.4% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | 44.6% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | 57.4% | – |
See a number that looks wrong?